ArticleVaccines2022

Development of a T Cell-Based COVID-19 Vaccine Using a Live Attenuated Influenza Vaccine Viral Vector.

Irina Isakova-Sivak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.